Trial
NCT03602261
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OPKO Health, Inc.
Collaborators
—
Condition
Secondary Hyperparathyroidism Due to Renal Causes
Intervention
Calcifediol Oral Capsule
Why stopped
Cohort 1 completed and cohort 2 terminated prior to initiation per company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-03